Melanotan I (Afamelanotide)

Safety Risk: Melanotan I carries a specific, intrinsic concern that sets it apart from most peptides: as a melanocortin-1 receptor agonist it drives melanocyte activity, and the approved afamelanotide program formally mandates dermatology skin surveillance precisely because chronic MC1R stimulation can darken existing moles and could in principle mask or promote melanoma. This is not generic class hand-waving; it is the named, intervention-distinguishing risk flagged in the regulatory program and the reason SCENESSE patients undergo scheduled skin exams. The score is held below the catastrophic floor only because the available cohorts have not shown a clear melanoma increase: Bohm et al. 2025 did not find a clear melanoma signal with chronic MC1R activation. Anyone using Melanotan I should treat ongoing dermatologic monitoring as non-negotiable, not optional.

Side Effect Profile: Melanotan I produces a meaningful but mostly non-severe side effect burden in regulated use. Nausea, fatigue, headache, implant-site reactions, generalized pigment change, and nevus darkening do most of the work, with nausea reported in roughly 18.5% of users. Homey et al. 2025 recorded adverse events in 87% of a German cohort, yet most were mild, treatment retention stayed high, and serious events were uncommon. Melanotan I therefore sits in moderate side-effect territory: the frequency is high enough to take seriously, but the severity is generally manageable. This dimension is kept deliberately distinct from the melanoma surveillance concern, which lives in the Safety score rather than here among the routine tolerability issues.

Financial Cost: Melanotan I is expensive when scored against its legitimate access path, prescription SCENESSE, because the implant is specialty-distributed and physician-administered rather than picked up over the counter. The cost score reflects the genuine regulated program plus the specialist visits, placement appointments, and follow-up exams that accompany it. Melanotan I is not a budget intervention under this framing, and the score is intentionally tied to the real medical channel rather than to cheaper unapproved sourcing. Treating the legitimate cost honestly matters because the apparent savings of gray-market alternatives come bundled with quality and safety uncertainties that are addressed separately in the Verdict, not discounted into this dimension.

Time/Effort Burden: Melanotan I demands moderate ongoing effort in regulated use. A proper protocol involves clinician implant placement, post-dose observation practice, periodic skin examinations, seasonal planning around sun exposure, and continued UV-behavior discipline rather than a simple daily pill. Melanotan I is clearly more work than an oral supplement, which is why the effort score lands in the middle of the range. The burden no longer folds in home reconstitution, dosing math, or product verification, because those belong to the unapproved sourcing path and are surfaced in the Verdict instead. Scored on the legitimate program, the effort is real but bounded and predictable for someone committed to the medical use case.

Opportunity Cost: Melanotan I has a modest opportunity cost because well-established, lower-risk tools cover much of the same ground for most people. Sunscreen, protective clothing, shade, gradual sun acclimation, and antioxidant-supportive nutrition are proven photoprotection foundations that carry none of the melanocyte-stimulation concerns. Melanotan I becomes more defensible when those approaches genuinely fail or when a condition like EPP redefines the baseline problem. The score stays moderate rather than low because casual users risk trading reliable UV-protection habits for a peptide that still requires the same sun respect, meaning the intervention can displace simpler safeguards without removing the underlying need for them.

Dependency/Withdrawal: Melanotan I has low dependency risk. There is no addictive pharmacology, no recognized withdrawal syndrome, and no physiologic trap that compels continued use. Melanotan I benefits do fade as pigment normalizes, and some users feel pulled toward repeat seasonal cycles before high-UV travel, but that pattern is a functional preference rather than true dependence. The score sits near the bottom of the risk scale because stopping carries no chemical penalty. The only practical pull is cosmetic or photoprotective desire, which a user can weigh deliberately rather than being driven by the molecule itself, keeping this dimension a genuine strength for Melanotan I.

Reversibility: Melanotan I is only partly reversible, which is why this score sits low-to-moderate rather than favorable. The transient effects resolve cleanly: nausea, fatigue, and headache fade after stopping. The pigment effects do not, because generalized tanning and especially mole darkening can persist for weeks to months and then continue evolving as skin renews. Melanotan I therefore requires continued dermatology follow-up after discontinuation, since a darkened or changing lesion that was masked during use is not a clean stop-and-reset situation. The reversibility score follows this split honestly: the symptom side unwinds quickly, but the pigment and surveillance obligations linger well past the last dose.